Galmed Pharmaceuticals Lt... (GLMD)
1.97
-0.17 (-7.94%)
At close: Mar 03, 2025, 3:54 PM
1.94
-1.52%
After-hours: Mar 03, 2025, 04:18 PM EST
Galmed Pharmaceuticals Ltd. Income Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
| Revenue | n/a | n/a | n/a | n/a | n/a | 2.04M | 1.08M | 467K | n/a | n/a | n/a | n/a |
| Cost of Revenue | 31K | 35K | 42K | 39K | 35K | n/a | n/a | n/a | 50K | n/a | n/a | n/a |
| Gross Profit | -31K | -35K | -42K | -39K | -35K | 2.04M | 1.08M | 467K | -50K | n/a | n/a | n/a |
| Operating Income | 7.49M | -17.65M | -32.88M | -30.21M | -22.38M | -10.71M | -12.36M | -16.88M | -10.88M | -9.14M | -14.57M | -3.14M |
| Interest Income | 375K | 297K | 562K | 1.19M | 1.92M | 959K | 65K | 35K | 253K | 40K | n/a | 6.00 |
| Pretax Income | -6.91M | -17.87M | -32.47M | -28.77M | -20.46M | -9.78M | -12.3M | -16.85M | -10.62M | -9.1M | -17.48M | -3.14M |
| Net Income | -6.91M | -18.57M | -31.95M | -27.61M | -18.54M | -9.86M | -12.3M | -16.95M | -10.62M | -9.1M | -17.48M | -3.15M |
| Selling & General & Admin | 3.92M | 4.66M | 5.66M | 4.13M | 4.2M | 4.44M | 3.8M | 3.08M | 3.25M | 2.48M | 7.36M | 694K |
| Research & Development | 3.57M | 12.99M | 27.22M | 26.08M | 18.18M | 8.31M | 9.65M | 14.27M | 7.63M | 6.66M | 7.21M | 2.44M |
| Other Expenses | -14.98M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -10K | n/a |
| Operating Expenses | -7.49M | 17.65M | 32.88M | 30.21M | 22.38M | 12.75M | 13.45M | 17.35M | 10.88M | 9.14M | 14.56M | 3.14M |
| Interest Expense | 11K | 215K | 43K | 31K | 33K | 42K | 49K | 67K | n/a | n/a | 34K | n/a |
| Selling & Marketing Expenses | 200K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | -7.49M | 17.65M | 32.88M | 30.21M | 22.38M | 12.75M | 13.45M | 17.35M | 10.88M | 9.14M | 14.56M | 3.14M |
| Income Tax | n/a | 705K | -519K | -1.16M | -1.92M | 75K | 12.36M | 106K | 21.24M | 1K | 1K | 6K |
| Shares Outstanding (Basic) | 230K | 1.68M | 1.64M | 1.42M | 1.41M | 1.21M | 832.49K | 758.31K | 740.03K | 688.25K | 711.66K | 337.96K |
| Shares Outstanding (Diluted) | 230.79K | 1.68M | 1.64M | 1.42M | 1.41M | 1.21M | 832.49K | 758.31K | 740.03K | 688.25K | 711.66K | 337.96K |
| EPS (Basic) | -30.05 | -11.08 | -19.48 | -19.46 | -13.17 | -8.15 | -14.77 | -22.36 | -14.35 | -13.23 | -24.57 | -9.32 |
| EPS (Diluted) | -29.95 | -11.08 | -19.48 | -19.46 | -13.17 | -8.15 | -14.77 | -22.36 | -14.35 | -13.23 | -24.57 | -9.32 |
| EBITDA | -6.87M | -17.62M | -32.84M | -30.17M | -22.34M | -10.33M | -12.13M | -16.71M | -10.82M | -9.13M | -14.57M | -3.13K |
| Depreciation & Amortization | 31K | 35K | 42K | 39K | 35K | 387K | 239K | 169K | 50K | 9K | 4K | 5K |